{
    "id": 1184,
    "fullName": "HRAS mutant",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "HRAS mutant indicates an unspecified mutation in the HRAS gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 3265,
        "geneSymbol": "HRAS",
        "terms": [
            "HRAS",
            "C-BAS/HAS",
            "C-H-RAS",
            "C-HA-RAS1",
            "CTLO",
            "H-RASIDX",
            "HAMSV",
            "HRAS1",
            "p21ras",
            "RASH1"
        ]
    },
    "variant": "mutant",
    "createDate": "07/28/2014",
    "updateDate": "10/03/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 5174,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, mouse models of bladder cancer harboring an HRAS mutation were sensitive to Glucophage (metformin), resulting in tumor growth reduction and prevention of hyperplasia regression (PMID: 26921394).",
            "molecularProfile": {
                "id": 1208,
                "profileName": "HRAS mutant"
            },
            "therapy": {
                "id": 1031,
                "therapyName": "Metformin",
                "synonyms": null
            },
            "indication": {
                "id": 11054,
                "name": "urinary bladder cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4943,
                    "pubMedId": 26921394,
                    "title": "High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with \u223c240-Fold Higher Drug Concentration in Urine than Serum.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26921394"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6737,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human urinary transitional cell carcinoma cells harboring mutant HRAS were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 1208,
                "profileName": "HRAS mutant"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 2671,
                "name": "transitional cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19448,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Zarnestra (tipifarnib) treatment resulted in an overall response rate of 53% (8/15, 8 partial response) in patients with head and neck squamous cell carcinoma harboring HRAS missense mutations at a variant allele frequency over 35%, and stable disease in 5 patients, with a median progression-free survival of 5.4 months (AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Oct 2019, abstract PR08; NCT02383927).",
            "molecularProfile": {
                "id": 1208,
                "profileName": "HRAS mutant"
            },
            "therapy": {
                "id": 938,
                "therapyName": "Tipifarnib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17085,
                    "pubMedId": null,
                    "title": "Preliminary results from a phase 2 trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations.",
                    "url": "https://eventpilotadmin.com/web/planner.php?id=AACR19MT"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1689,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib study, Alpelisib (BYL719) in combination with Binimetinib (MEK162) demonstrated preliminary safety and efficacy in patients with RAS-mutant advanced solid tumors, including patients with ovarian cancer (J Clin Oncol 32:5s, 2014 (suppl; abstr 9051).",
            "molecularProfile": {
                "id": 1208,
                "profileName": "HRAS mutant"
            },
            "therapy": {
                "id": 1311,
                "therapyName": "Alpelisib + Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 1765,
                    "pubMedId": null,
                    "title": "A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors.",
                    "url": "http://meetinglibrary.asco.org/content/129278-144"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12218,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, breast cancer cell lines harboring RAS mutations, including HRAS-mutant cell lines, demonstrated decreased sensitivity to growth inhibition by PI-273, in culture (PMID: 28827373).",
            "molecularProfile": {
                "id": 1208,
                "profileName": "HRAS mutant"
            },
            "therapy": {
                "id": 6363,
                "therapyName": "PI-273",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 10169,
                    "pubMedId": 28827373,
                    "title": "PI-273, a Substrate-Competitive, Specific Small-Molecule Inhibitor of PI4KII\u03b1, Inhibits the Growth of Breast Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28827373"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9466,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human solid tumor cell lines harboring HRAS mutations demonstrated increased sensitivity to growth inhibition by Afinitor (everolimus) in culture compared to cell lines with wild-type HRAS (PMID: 26544513).",
            "molecularProfile": {
                "id": 1208,
                "profileName": "HRAS mutant"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7197,
                    "pubMedId": 26544513,
                    "title": "Mutant HRAS as novel target for MEK and mTOR inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26544513"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6692,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited growth of human endometrial cancer cells harboring mutant HRAS in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 1208,
                "profileName": "HRAS mutant"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9457,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Binimetinib (MEK162) inhibited growth and induced apoptosis in human solid tumor cell lines harboring HRAS mutations in culture (PMID: 26544513).",
            "molecularProfile": {
                "id": 1208,
                "profileName": "HRAS mutant"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7197,
                    "pubMedId": 26544513,
                    "title": "Mutant HRAS as novel target for MEK and mTOR inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26544513"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9456,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human solid tumor cell lines harboring HRAS mutations demonstrated increased sensitivity to growth inhibition by Selumetinib (AZD6244) in culture compared to cell lines with wild-type HRAS (PMID: 26544513).",
            "molecularProfile": {
                "id": 1208,
                "profileName": "HRAS mutant"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7197,
                    "pubMedId": 26544513,
                    "title": "Mutant HRAS as novel target for MEK and mTOR inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26544513"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10387,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, Cometriq (cabozantinib) treatment resulted in improved progression free survival (47 vs 8 weeks) compared to placebo in thyroid medullary carcinoma patients harboring RAS mutations (PMID: 27525386).",
            "molecularProfile": {
                "id": 1208,
                "profileName": "HRAS mutant"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 3973,
                "name": "thyroid gland medullary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8408,
                    "pubMedId": 27525386,
                    "title": "Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27525386"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20965,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination therapy of Buparlisib (BKM120) and Selumetinib (AZD6244) led to a synergistic effect, resulting in growth inhibition of astrocytoma cells with an HRAS mutation and expressing PIK3CA R88Q in culture, but at a higher drug concentration compared to cells without mutant HRAS (PMID: 29975751).",
            "molecularProfile": {
                "id": 35457,
                "profileName": "HRAS mut PIK3CA R88Q"
            },
            "therapy": {
                "id": 4652,
                "therapyName": "Buparlisib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3070,
                "name": "malignant glioma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18213,
                    "pubMedId": 29975751,
                    "title": "PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29975751"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20966,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination therapy of Buparlisib (BKM120) and Selumetinib (AZD6244) led to a synergistic effect, resulting in growth inhibition of astrocytoma cells with an HRAS mutation expressing PIK3CA E542K in culture, but at a higher drug concentration compared to cells without mutant HRAS (PMID: 29975751).",
            "molecularProfile": {
                "id": 35458,
                "profileName": "HRAS mut PIK3CA E542K"
            },
            "therapy": {
                "id": 4652,
                "therapyName": "Buparlisib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3070,
                "name": "malignant glioma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18213,
                    "pubMedId": 29975751,
                    "title": "PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29975751"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20964,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination therapy of Buparlisib (BKM120) and Selumetinib (AZD6244) led to a synergistic effect, resulting in growth inhibition of astrocytoma cells with an HRAS mutation and expressing PIK3CA M1043V in culture, but at a higher drug concentration compared to cells without mutant HRAS (PMID: 29975751).",
            "molecularProfile": {
                "id": 35460,
                "profileName": "HRAS mut PIK3CA M1043V"
            },
            "therapy": {
                "id": 4652,
                "therapyName": "Buparlisib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3070,
                "name": "malignant glioma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18213,
                    "pubMedId": 29975751,
                    "title": "PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29975751"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1208,
            "profileName": "HRAS mutant",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35457,
            "profileName": "HRAS mut PIK3CA R88Q",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35458,
            "profileName": "HRAS mut PIK3CA E542K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35459,
            "profileName": "HRAS mut PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35460,
            "profileName": "HRAS mut PIK3CA M1043V",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}